Amyris Prices $600.0 Million Of 1.50% Convertible Senior Notes Due 2026

EMERYVILLE, Calif.: EMERYVILLE, Calif., Nov. 10, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026 (the "notes")....

Click to view original post